Bausch Health is rumored to be looking to sell its Bausch + Lomb business, which will ease bankruptcy concerns and upgrade ...

Bausch + Lomb is exploring a sale as its parent company, Bausch Health, faces significant debt and creditors' opposition to a ...

Bausch + Lomb shares popped following a report that the eyecare company is considering selling itself, to separate from its ...

Bausch + Lomb is assessing interest from potential buyers as a way around the roadblock, the FT wrote. The company had a market cap of $6.27 billion on Monday.

Bausch + Lomb stock surged Monday — briefly breaking out — on a report the company is working with advisors to explore a potential sale.

This suit was surfaced by Law.com Radar, ALM's source for immediate alerting on just filed cases in state and federal courts.

Financial analyst predicts Bausch & Lomb (BLCO) could be worth $28/share in a potential takeover, with private equity ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Bausch + Lomb Corporation (BLCO – Research Report) yesterday and set a ...

Bausch + Lomb BLCO shares ended the last trading session 14.5% higher at $17.80. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This ...

In a report released yesterday, Larry Biegelsen from Wells Fargo assigned a Buy rating on Bausch + Lomb Corporation (BLCO – Research ...

Bausch + Lomb rose in premarket trading Monday after the Financial Times reported that it is considering selling itself as a way to separate from Bausch Health, its indebted parent company. Shares ...